Envoy Medical Appoints Chief Accounting Officer Robert Potashnick

What Happened
Envoy Medical, Inc. announced on August 27, 2026 that it has appointed Robert Potashnick as its Chief Accounting Officer and Vice President of Finance pursuant to an Employment Agreement dated August 24, 2026. Mr. Potashnick had been serving as the company’s Interim Chief Financial Officer on a contractor basis and will continue as the company’s principal financial officer and principal accounting officer. His compensation package includes a $315,000 annual base salary, an initial target bonus equal to 15% of base salary tied to performance goals, an initial equity award of 250,000 stock options at an exercise price of $0.746 per share (the closing price on the hire date), and six months of severance for certain terminations.

Key Details

• Employment Agreement dated August 24, 2026; appointment disclosed in 8-K filed August 27, 2026.
• Base salary: $315,000 per year; initial target bonus: 15% of base salary.
• Initial equity: 250,000 stock options at $0.746 exercise price.
• Six months’ severance payable under certain termination scenarios.
• Background: Mr. Potashnick (46) provided consulting via Oasis Business Consulting, LLC since Oct 2024 and worked for Envoy beginning June 2025; prior CFO roles include FOXO Technologies and Flutterbee; earlier roles at UnitedHealth Group and PwC.

Why It Matters
This change formalizes the company’s finance leadership by converting the interim/contractor finance chief into the named principal financial and accounting officer, which affects who is responsible for financial reporting and regulatory filings. The compensation and option grant are material for assessing executive incentives and potential future share dilution. Investors should note the continuity in leadership but also track any future disclosures where Mr. Potashnick, as principal financial officer, may sign or certify financial statements.